Anti-vascular endothelial growth factor (VEGF) injections represent generally a first-line therapy for several retinal disorders including DME (Heier et al., 2012; Reibaldi et al., 2014; Schmidt-Erfurth et al., 2017; Plyukhova et al., 2020), but monthly injections are needed at least during the loading dose (Schmidt-Erfurth et al., 2017). The gene discussed is VEGFA; the disease is retinal disorder.